GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...
The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...
Hosted on MSN17h
FDA beats EMA to most approved new drugs in 2024On 15 January, the two agencies released respective lists of medicines approved last year. The FDA approved 50 novel drugs ...
Hosted on MSN23h
Biogen's Quarterly Earnings Preview: What You Need to KnowBiogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and ...
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.
Ozempic, Rybelsus and Wegovy top the list of the newest drugs selected for Medicare Part price negotiation, part of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback